Results 191 to 200 of about 901,780 (213)

Paramagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem, Angel Liu, Sargis Manukyan, Mustafa Subhi, Elaina Luskin, Bryan Quah, Sreekanth Madhusoodhanan Nair, Arzu C. Has Silemek, Gabriela Zabala, Yujie Cui, Laura Locke, Paula Barreras, Marwa Kaisey, Vinicius Calsavara, Daniel S. Reich, Nancy L. Sicotte, Pascal Sati, Omar Al‐Louzi   +17 more
wiley   +1 more source

Thermostability and binding properties of single-chained Fv fragments derived from therapeutic antibodies. [PDF]

Protein Sci
Tadokoro T, Tsuboi H, Nakamura K, Hayakawa T, Ohmura R, Kato I, Inoue M, Tsunoda SI, Niizuma S, Okada Y, Otsuguro S, Maenaka K.   +11 more
europepmc   +1 more source

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies. [PDF]

Int J Mol Sci
de Jonge AV, Csikós T, Eken M, Bulthuis EP, Poddighe PJ, Roemer MGM, Chamuleau MED, Mutis T.   +7 more
europepmc   +1 more source

Therapeutic antibodies: technical points to consider in tissue cross-reactivity studies. [PDF]

J Toxicol Pathol
Fujii E, Kato A.
europepmc   +1 more source

Structure and function of therapeutic antibodies approved by the US FDA in 2023. [PDF]

Antib Ther
Strohl WR.
europepmc   +1 more source

Establishing Multi-Dimensional LC-MS Systems for Versatile Workflows to Analyze Therapeutic Antibodies at Different Molecular Levels in Routine Operations. [PDF]

Pharmaceuticals (Basel)
Heinrich K, Hoelterhoff S, Oezipek S, Winter M, Rainer T, Hourtoulle L, Grunert I, Graf T, Leiss M, Bathke A.   +9 more
europepmc   +1 more source

Using IMGT unique numbering for IG allotypes and Fc-engineered variants of effector properties and half-life of therapeutic antibodies. [PDF]

Immunol Rev
Lefranc MP, Lefranc G.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapeutic Monoclonal Antibodies against Cancer: Present and Future

Cells, 2023
J A Garcia-Sanz, Marisa Delgado Alvarez, Garcia-Sanz JOSÉ A   +2 more
exaly  

A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19

International Journal of Molecular Sciences, 2021
Syed İmam Rabbani, Mohd Imran Ansari, Syed Mohammed Basheeruddin Asdaq   +2 more
exaly  

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies

International Journal of Molecular Sciences, 2021
Ger Van Zandbergen, Zoe Waibler, Martina Anzaghe   +2 more
exaly